CDKN2B-AS1 and lung cancer: In addition, while five articles demonstrate upregulation of ANRIL in non-small cell lung cancer and adenocarcinoma (NSCLC/LUAD) [48,66,85,86,87], one study reports the opposite effect in idiopathic pulmonary fibrosis (IPF), an independent risk factor of lung cancer with NSCLC being the main pathological type [88,89,90].